EMA: First Adapted COVID-19 Vaccines Expected In September
Data Still Awaited On Valneva Vaccine & Molnupiravir
Executive Summary
As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.
You may also be interested in...
Coronavirus Notebook: Adapted Comirnaty Vaccine Under EU Review, Sanofi & GSK Laud Next-Gen Booster
Valneva expects its vaccine candidate to be approved this month. Meanwhile, the core functions of the UK’s Vaccine Taskforce are to be transferred to the UK Health Security Agency and the Office for Life Sciences.
Coronavirus Notebook: Moderna Postpones EU Spikevax Supplies, Industry Insists TRIPS Waiver Is Redundant
The medical NGO, MSF, has urged countries not to adopt the latest draft of the proposed waiver, saying it would impair efforts to boost access to COVID-19 products around the world. The WHO has been looking at the benefits of hybrid immunity – and how far it might be waning.
Coronavirus Notebook: New EU Body To Advise On Future Pandemic Actions, Valneva Awaits EMA Verdict On Vaccine Candidate
French health tech firm NOVA has produced a model for assessing the impact of non-pharmaceutical COVID-19 interventions on clinical trials of respiratory tract drugs, and Moderna’s Spikevax has been OKd for younger children in Great Britain.